|
|
T-20 (Enfuvirtide, Fuzeon) Research
- Needle-Free Mode of T-20 Dosing Looks Highly Satisfactory for Patients (August 28, 2006)
From aidsmap.com
- HIV JournalView: Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006 (July 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
From U.S. Food and Drug Administration
- Fuzeon Recommended for CD4 Counts Over 100, Viral Loads Below 100,000 (October 2004)
Quick recap of recommendations published in the journal AIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
- HIV JournalView: Long-Term Resistance Patterns on Enfuvirtide (September 2004)
From The Body PRO
- Enfuvirtide Benefits Persist for at Least 2 Years (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO
- Global Guidelines Published on Enfuvirtide Use (May 18, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Drug Development News: Trimeris (May/June 2004)
Efforts are under way to improve the delivery method of T-20.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Enfuvirtide Safe and Effective for Adolescents (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Food and Drug Administration Approves First in Class of AIDS Drugs (March 14, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (March 13, 2003)
Results published early from the TORO-1 study investigating T-20 in treatment-experienced patients.
To read PDF, click here
In New England Journal of Medicine
- Fuzeon (T-20), the First HIV Entry Inhibitor, Is Now FDA-Approved (Spring 2003)
In STEP Perspective, from Seattle Treatment Education Project
- Fuzeon Data Review (March 2003)
A capsule review of T-20 efficacy data from TORO 1 and TORO 2.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Anti-HIV Drug Updates -- Three Drugs on the Near Horizon (January 2003)
Research from Barcelona on T-20, atazanavir and emtricitabine.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Anti-HIV Drug Updates: T-20 (Enfuvirtide/Fuzeon) (January 2003)
In Project Inform Perspective, from Project Inform
- Boulder Blues (January/February 2003)
Roche meets with ADAPs and activists to discuss T-20 (Fuzeon) pricing.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Informed Access to T-20 Planned (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- New Anti-HIV Therapies: Pentafuside (T-20) (January 2003)
From Project Inform
- Research From the 42nd ICAAC: T-20 License -- and Ultimate Trial -- Loom (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Study Shows T-20 Highly Effective as Regimen Booster (November 19, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Digging Deeper at the Resistance Workshop (August 14, 2002)
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Long-Term Treatment With Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living (August 6, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
- T-20 Study Data Promising (June/July 2002)
In Positive Living, from AIDS Project Los Angeles
- AIDS Drug Fares Well in Big Trial (April 19, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- T-20: Will Long-Term Use Weaken the Immune System's Ability to Fight HIV? (June 11, 2001)
From Canadian AIDS Treatment Information Exchange
- Experimental Entry Inhibitor Drugs (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Low-Dose Ritonavir and Efavirenz in Non-Nucleoside-Naive Protease-Inhibitor-Experienced HIV-1 Infected Adults (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- AIDS Researchers Explore New Drug Options (March 1, 2000)
In Journal of the American Medical Association
- T-20: 5-Drug Combination Trial for Heavily Treated NNRTI-Naive Patients (July 16, 1999)
From AIDS Treatment News
- Safety, Pharmacokinetics, and Antiviral Activity of T-20 as a Single Agent in Heavily Pre-Treated Patients (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- T-20 Results Published (November 6, 1998)
From AIDS Treatment News
- Fusion Inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approaches (July 17, 1998)
From AIDS Treatment News
- T-20 and Trimeris (April 17, 1998)
In AIDS Treatment News, from AIDS Treatment News
- T-20: Entirely New Antiretroviral (September 19, 1997)
From AIDS Treatment News
|
|
